Colorectal cancer remains one of the most preventable yet persistently lethal malignancies worldwide — largely because current screening tools fail at the intersection of sensitivity and patient compliance. The gap between what colonoscopy can theoretically catch and what it actually catches in practice is enormous, and closing that gap could meaningfully shift survival statistics for millions of adults each year.
This review in Clinica Chimica Acta maps the current frontier of non-invasive detection strategies, focusing on liquid biopsy platforms that analyze circulating tumor DNA (ctDNA) and microRNAs (miRNAs) in peripheral blood. Beyond these, the authors catalog emerging signal sources across six molecular dimensions: genomic mutations, epigenomic methylation patterns, gut microbiome compositional shifts, metabolomic signatures, and proteomic profiles. Each layer adds discriminating power, particularly in distinguishing early-stage lesions from benign colorectal conditions — a precision challenge that single-marker assays have historically failed to meet.
The broader significance here lies in convergence. No single biomarker class reviewed has yet achieved standalone clinical-grade sensitivity for stage I-II CRC detection, but multi-omics panel strategies are closing that gap faster than any prior generation of tools. Methylation-based liquid biopsies, such as the approach underlying FDA-cleared blood tests already entering clinical practice, represent the most translationally mature branch of this work. MiRNA panels, by contrast, remain largely in validation phases across heterogeneous cohorts. A critical limitation of the current landscape — acknowledged implicitly by the review's breadth — is that most studies are observational, single-cohort, and lack longitudinal follow-up sufficient to assess lead-time bias. For health-conscious adults, the practical takeaway is forward-looking: within five years, routine blood-based CRC screening panels incorporating at least ctDNA and epigenomic methylation markers appear credible. This review is best read as an evidence map for what's coming, not yet what's here.